Keeping lupus patients on hydroxychloroquine during the COVID-19 pandemic.


Journal

Cleveland Clinic journal of medicine
ISSN: 1939-2869
Titre abrégé: Cleve Clin J Med
Pays: United States
ID NLM: 8703441

Informations de publication

Date de publication:
11 May 2020
Historique:
entrez: 13 5 2020
pubmed: 13 5 2020
medline: 13 5 2020
Statut: aheadofprint

Résumé

Hydroxychloroquine (HCQ) is in short supply as a result of the coronavirus disease 2019 (COVID-19) pandemic, presenting a challenge to rheumatologists to ensure their patients with systemic lupus erythematosus (SLE) continue to take this essential drug. HCQ is the only SLE treatment shown to increase survival and any change in the HCQ regimen is potentially dangerous. Changes in the HCQ regimen should be made jointly with the patient after a discussion of the available evidence and expert opinion and the patient's preferences. Providers need to make thoughtful, informed decisions in this time of medication shortage.

Identifiants

pubmed: 32393597
pii: ccjm.87a.ccc023
doi: 10.3949/ccjm.87a.ccc023
pii:
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Informations de copyright

Copyright © 2020 The Cleveland Clinic Foundation. All Rights Reserved.

Auteurs

Emily Littlejohn (E)

Department of Rheumatologic and Immunologic Disease, Cleveland Clinic.

Classifications MeSH